Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Transbuccal insulin - MidaSol

Next Previous
Drug Profile

Transbuccal insulin - MidaSol

Alternative Names: Insulin - MidaSol; Insulin buccal soluble film - Biodexa Pharmaceuticals; Insulin nanoparticles buccal film - Midasol; MidaForm insulin PharmFilm; MidaForm™-Insulin-Pharmfilm®; MSL-001; MSRX-301; MTD-101; Nanoparticle insulin

Latest Information Update: 16 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MidaSol Therapeutics; Midatech; MonoSol Rx
  • Developer MidaSol Therapeutics
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 03 Dec 2018 Discontinued - Phase-II for Type 1 diabetes mellitus in Australia (Buccal)
  • 27 Jul 2015 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (Buccal) (ACTRN12615000495527)
  • 01 Jul 2015 Midatech and Monosol plan a phase II trial Type-I diabetes mellitus in Australia (ACTRN12615000495527)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top